Results 141 to 150 of about 1,810 (157)

Association between Stroke History and Clinical Events in Atrial Fibrillation Patients after Valve Replacement. [PDF]

Rev Cardiovasc Med
Yan X, Lian S, Wang D, Yan B, Zhang L, Zhang Z.   +5 more
europepmc   +1 more source

Differences in vasomotor function of mesenteric arteries between Ossabaw minipigs with predisposition to metabolic syndrome and Göttingen minipigs.

Am J Physiol Heart Circ Physiol
Eickelmann C, Lieder HR, Sturek M, Heusch G, Kleinbongard P.   +4 more
europepmc   +1 more source

Abstract 14011: Rare Variants in GUCY1A3 Gene Contribute to Hypertension via NO/cGMP Pathway

Circulation, 2022
Hypertension is a leading risk factor for cardiovascular events and considered as a complex genetic disease. Previous studies have revealed many common variants relevant to hypertension. However, the contributions of rare variants and the underlying mechanisms are still poorly understood.
Chen Li, Jing Wang, Chao Xing, Minjie Lu, Yuming Zhu, Xueyi Wu, Yibing Shao, Yubao Zou, Lei Song, Jizheng Wang   +9 more
openalex   +2 more sources

Abstract 14092: Reduction of Atherosclerosis in Gucy1a3 Deficient Mice

Circulation, 2015
Introduction: GUCY1A3 encodes the α1 subunit of the soluble guanylate cyclase (sGC) and has been associated with CAD/MI by genome-wide association studies (GWAS) and in a rare extended family with MI. The α1 and the β1 subunit form the heterodimeric sGC, the nitric oxide (NO) receptor.
María Segura‐Puimedon, Evanthia Mergia, Jaafar Al‐Hasani, Rédouane Aherrahrou, Jennifer Freyer, Cor de Wit, Doris Kösling, Heribert Schunkert, Jeanette Erdmann, Zouhair Aherrahrou   +9 more
openalex   +2 more sources

Stimulators of the soluble guanylyl cyclase: promising functional insights from rare coding atherosclerosis-related GUCY1A3 variants

Basic Research in Cardiology, 2016
Stimulators of the soluble guanylyl cyclase (sGC) are emerging therapeutic agents in cardiovascular diseases. Genetic alterations of the GUCY1A3 gene, which encodes the α1 subunit of the sGC, are associated with coronary artery disease. Studies investigating sGC stimulators in subjects with CAD and carrying risk-related variants in sGC are, however ...
Jana Wobst, Simon von Ameln, Bernhard Wolf, Michael Wierer, Tan An Dang, Hendrik B. Sager, Stephanie Tennstedt, Christian Hengstenberg, Doris Koesling, Andreas Friebe, Siegmund Braun, Jeanette Erdmann, Heribert Schunkert, Thorsten Kessler   +13 more
openalex   +4 more sources

Abstract 15483: Functional Relevance of Rare GUCY1A3 Variants in Patients Affected by Premature Myocardial Infarction

Circulation, 2015
Introduction: Myocardial infarction (MI) is the main complication of coronary artery disease (CAD). Recently, a locus tagging the GUCY1A3 gene has been shown to be genome-wide significantly associated with CAD. GUCY1A3 encodes the α1 subunit of the soluble guanylyl cyclase (sGC), a heterodimer composed of α1 and β1 subunits ...
Jana Wobst, Tan An Dang, Thorsten Kessler, Simon von Ameln, Stephanie Tennstedt, Christian Hengstenberg, Jeanette Erdmann, Heribert Schunkert   +7 more
openalex   +2 more sources

Inhibition of angiogenesis in human glioma cell lines by antisense RNA from the soluble guanylate cyclase genes, GUCY1A3 and GUCY1B3

Oncology Reports, 2004
Malignant gliomas, most of which show an elevated level of vascular endothelial cell growth factor (VEGF) expression, are well known for their hyper-vascularity. One of the possible inducers of VEGF in tumor cells is nitric oxide (NO), which is synthesized by NO synthase and stimulates soluble guanylate cyclase (GC) in tumor cells. Here, we report that
Makoto Saino, Tomoko Maruyama, Takao Sekiya, Takamasa Kayama, Yoshinori Murakami   +4 more
openalex   +3 more sources

Open angle glaucoma in soluble guanylate cyclase α1-deficient mice and its association with the GUCY1A3/GUCY1B3 locus in humans

Nitric Oxide, 2012
Primary open angle glaucoma (POAG) is a leading cause of blindness, due to irreversible retinal ganglion cell (RGC) loss with optic nerve (ON) degeneration. Currently, there is no cure for POAG and available therapies offer incomplete protection, highlighting the need for novel drug targets.
Emmanuel S. Buys, Yu‐Chieh Ko, Jae-Hee Kang, Douglas J. Rhee, Peter Brouckaert, Janey L. Wiggs, Meredith Gregory‐Ksander, Louis R. Pasquale, Kenneth D. Bloch, Bruce R. Ksander, Stephanie Loomis, Jae-Hee Kang, Haiyan Gong, Douglas Rhee, Peter Brouckaert, Janey Wiggs, Meredith Gregory, Louis Pasquale, Kenneth Bloch, Bruce Ksander   +19 more
openalex   +2 more sources

Moyamoya Disease 6 with Achalasia Due to GUCY1A3 Mutation in a Child

Neurology India, 2020
Venkateswari Ramesh, Janani Sankar
openalex   +3 more sources

Platelet Inhibition In Carriers Of The Gucy1A3 Coronary Artery Disease Risk Allele

Atherosclerosis, 2019
Laura Lambrecht, Jana Wobst, Bernhard Wolf, Heribert Schunkert, Thorsten Kessler   +4 more
openalex   +2 more sources